Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.
| Revenue (TTM) | $5.69B |
| Gross Profit (TTM) | $1.09B |
| EBITDA | $405.09M |
| Operating Margin | 5.90% |
| Return on Equity | 16.00% |
| Return on Assets | 6.17% |
| Revenue/Share (TTM) | $36.17 |
| Book Value | $8.41 |
| Price-to-Book | 2.78 |
| Price-to-Sales (TTM) | 0.82 |
| EV/Revenue | 0.803 |
| EV/EBITDA | 11.12 |
| Quarterly Earnings Growth (YoY) | 12.90% |
| Quarterly Revenue Growth (YoY) | 1.90% |
| Shares Outstanding | $149.79M |
| Float | $147.71M |
| % Insiders | 1.28% |
| % Institutions | 108.75% |
Volatility is currently expanding
MONSEY, N.Y., Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Option Care Health, Inc. (NASDAQ: OPCH) (“OPCH”) to CD&R and McKesson Corporation for $32.05 per share in cash.
LOS ANGELES--(BUSINESS WIRE)---- $OPCH--OPCH Investors Have Opportunity to Join Option Care Health, Inc. Fraud Investigation with SBS Law.
NEW YORK, Oct. 11, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Option Care Health, Inc. (NASDAQ: OPCH ) related to its sale to an investor group comprised of affiliates of Clayton, Dubilier & Rice, LLC and McKesson Corporation.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Option Care Health, Inc. (NasdaqGS: OPCH) to CD&R, McKesson Corporation. Under the terms of the proposed transaction, shareholders of Option Care will receive $32.05 in cash for each share of Option Care that they own. KSF is seeking to determine whether this consideration and the process t.
Option Care (OPCH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Option Care Health shareholders will receive just $32.05 per share, representing a total enterprise value of approximately $5.8 billion; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Oct. 6, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Option Care Health (NASDAQ: OPCH) by CD&R and McKesson Corporation, provides fair value to Option Care Health's public shareholders and whether Option Care Health's Board adequately protected shareholder interests in negotiating and approving the transaction. Are You a Option Care Health Shareholder?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BALA CYNWYD, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Mckesson Corp (NYSE:MCK), the US healthcare services and drug distribution company, and Clayton Dubilier & Rice (CD&R), the private investment firm, have agreed to acquire Option Care Health (NASDAQ:OPCH) for approximately $5.8 billion. The buyers will pay $32.05 a share for Option Care Health, the largest independent provider of home and alternate-site infusion services in the US, representing a 37% premium to Monday's closing price.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OPCH and any ticker you trade — then tracks every position and per-strategy win rate.
